Last reviewed · How we verify
indacaterol maleate/mometasone furoate
indacaterol maleate/mometasone furoate is a Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination Small molecule drug developed by Novartis. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD), Asthma. Also known as: QMF149.
Indacaterol maleate is a long-acting beta2-adrenergic receptor agonist, while mometasone furoate is an inhaled corticosteroid.
Indacaterol maleate is a long-acting beta2-adrenergic receptor agonist, while mometasone furoate is an inhaled corticosteroid. Used for Chronic obstructive pulmonary disease (COPD), Asthma.
At a glance
| Generic name | indacaterol maleate/mometasone furoate |
|---|---|
| Also known as | QMF149 |
| Sponsor | Novartis |
| Drug class | Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination |
| Target | beta2-adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Indacaterol maleate works by stimulating the beta2-adrenergic receptors in the lungs, causing bronchodilation and improving airflow. Mometasone furoate, on the other hand, reduces inflammation in the airways by inhibiting the production of pro-inflammatory cytokines.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma
Common side effects
- Cough
- Headache
- Oral candidiasis
- Upper respiratory tract infection
- Nausea
Key clinical trials
- Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma (PHASE2)
- Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma (PHASE2)
- Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma (PHASE2)
- Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- indacaterol maleate/mometasone furoate CI brief — competitive landscape report
- indacaterol maleate/mometasone furoate updates RSS · CI watch RSS
- Novartis portfolio CI
Frequently asked questions about indacaterol maleate/mometasone furoate
What is indacaterol maleate/mometasone furoate?
How does indacaterol maleate/mometasone furoate work?
What is indacaterol maleate/mometasone furoate used for?
Who makes indacaterol maleate/mometasone furoate?
Is indacaterol maleate/mometasone furoate also known as anything else?
What drug class is indacaterol maleate/mometasone furoate in?
What development phase is indacaterol maleate/mometasone furoate in?
What are the side effects of indacaterol maleate/mometasone furoate?
What does indacaterol maleate/mometasone furoate target?
Related
- Drug class: All Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination drugs
- Target: All drugs targeting beta2-adrenergic receptor
- Manufacturer: Novartis — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD)
- Indication: Drugs for Asthma
- Also known as: QMF149
- Compare: indacaterol maleate/mometasone furoate vs similar drugs
- Pricing: indacaterol maleate/mometasone furoate cost, discount & access